Skye Competitors
| SKYE Stock | USD 0.73 0.01 1.39% |
Skye Bioscience vs CEL SCI Correlation
Very poor diversification
The correlation between Skye Bioscience Common and CVM is 0.84 (i.e., Very poor diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Skye Bioscience Common and CVM in the same portfolio, assuming nothing else is changed.
Moving together with Skye Stock
Moving against Skye Stock
| 0.81 | IMMP | Immutep Ltd ADR | PairCorr |
| 0.72 | DSGN | Design Therapeutics | PairCorr |
| 0.6 | ENGN | enGene Holdings Common | PairCorr |
| 0.48 | 63E | ONWARD MEDICAL BV | PairCorr |
| 0.48 | KYTX | Kyverna Therapeutics | PairCorr |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Skye Bioscience's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Skye Bioscience Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Skye Bioscience and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Skye and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Skye Bioscience Common does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Skye Stock performing well and Skye Bioscience Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Skye Bioscience's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| ALGS | 4.62 | 0.19 | 0.03 | 0.55 | 5.16 | 11.50 | 28.43 | |||
| XLO | 2.13 | (0.71) | 0.00 | (0.64) | 0.00 | 4.17 | 15.41 | |||
| MRSN | 7.16 | 3.47 | 0.82 | 10.88 | 2.27 | 7.25 | 210.61 | |||
| INMB | 3.58 | (0.11) | (0.01) | 0.02 | 4.32 | 6.82 | 22.66 | |||
| XFOR | 3.20 | (0.08) | (0.01) | 0.04 | 3.78 | 7.57 | 23.09 | |||
| KZR | 0.75 | 0.05 | (0.02) | 0.29 | 0.99 | 1.60 | 7.79 | |||
| BRNS | 3.04 | (0.81) | 0.00 | 62.56 | 0.00 | 5.71 | 17.76 | |||
| LVTX | 1.33 | 0.17 | 0.05 | 0.98 | 1.19 | 4.70 | 14.75 | |||
| PDSB | 4.10 | (0.41) | 0.00 | (0.10) | 0.00 | 8.08 | 27.78 | |||
| CVM | 4.51 | (0.41) | 0.00 | (0.26) | 0.00 | 10.19 | 30.91 |
Cross Equities Net Income Analysis
Compare Skye Bioscience Common and related stocks such as Aligos Therapeutics, Xilio Development, and Mersana Therapeutics Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALGS | (13.9 M) | (13.9 M) | (13.9 M) | (13.9 M) | (13.9 M) | (13.9 M) | (13.9 M) | (13.9 M) | (13.9 M) | (52.3 M) | (108.5 M) | (128.3 M) | (96 M) | (87.7 M) | (131.2 M) | (118.1 M) | (124 M) |
| XLO | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (55.2 M) | (74.3 M) | (87.3 M) | (76.4 M) | (58.2 M) | (52.4 M) | (55 M) |
| MRSN | (16.4 M) | (16.4 M) | (16.4 M) | (16.4 M) | (16.4 M) | (16.4 M) | (13.7 M) | (38.7 M) | (64.3 M) | (28.2 M) | (88 M) | (170.1 M) | (204.2 M) | (171.7 M) | (69.2 M) | (62.3 M) | (65.4 M) |
| INMB | (48.9 K) | (48.9 K) | (48.9 K) | (48.9 K) | (48.9 K) | (48.9 K) | (277 K) | (831 K) | (12.4 M) | (7.7 M) | (12.1 M) | (30.3 M) | (28.6 M) | (30 M) | (42.1 M) | (37.9 M) | (36 M) |
| XFOR | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (23 M) | (33.9 M) | (43 M) | (56.6 M) | (62.1 M) | (88.7 M) | (93.9 M) | (101.2 M) | (37.5 M) | (33.7 M) | (35.4 M) |
| KZR | (9 M) | (9 M) | (9 M) | (9 M) | (9 M) | (9 M) | (9 M) | (8.5 M) | (23.2 M) | (31.5 M) | (39 M) | (54.6 M) | (65.3 M) | (101.9 M) | (83.7 M) | (75.4 M) | (71.6 M) |
| BRNS | (20.7 M) | (20.7 M) | (20.7 M) | (20.7 M) | (20.7 M) | (20.7 M) | (20.7 M) | (20.7 M) | (20.7 M) | (20.7 M) | (17.7 M) | (50.9 M) | 5.3 M | (73.3 M) | (61.1 M) | (55 M) | (57.7 M) |
| PDSB | (4.7 M) | (4.7 M) | (4.7 M) | (6.9 M) | (12.2 M) | (28.1 M) | (38.8 M) | (50.9 M) | (40.9 M) | (7 M) | (14.8 M) | (16.9 M) | (40.9 M) | (42.9 M) | (37.6 M) | (33.8 M) | (35.5 M) |
| CVM | (2.9 M) | (15.5 M) | (9.2 M) | (27.4 M) | (34.7 M) | (11.5 M) | (14.4 M) | (31.8 M) | (24.7 M) | (32.2 M) | (39.2 M) | (38.3 M) | (32.4 M) | (26.9 M) | (25.4 M) | (22.9 M) | (21.7 M) |
Skye Bioscience Common and related stocks such as Aligos Therapeutics, Xilio Development, and Mersana Therapeutics Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Skye Bioscience Common financial statement analysis. It represents the amount of money remaining after all of Skye Bioscience Common operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Skye Bioscience Competitive Analysis
The better you understand Skye Bioscience competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Skye Bioscience's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Skye Bioscience's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Skye Bioscience Competition Performance Charts
Five steps to successful analysis of Skye Bioscience Competition
Skye Bioscience's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Skye Bioscience Common in relation to its competition. Skye Bioscience's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Skye Bioscience in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Skye Bioscience's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Skye Bioscience Common, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Skye Bioscience position
In addition to having Skye Bioscience in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Adviser Favorites Thematic Idea Now
Adviser Favorites
Financial advisors frequently recommend that individuals diversify their investment portfolios with a mix of different types of stocks. These can include blue-chip stocks, growth stocks, and dividend stocks. The Adviser Favorites theme has 17 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Adviser Favorites Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Skye Bioscience Correlation with its peers. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Will Biotechnology sector continue expanding? Could Skye diversify its offerings? Factors like these will boost the valuation of Skye Bioscience. If investors know Skye will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Skye Bioscience data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of Skye Bioscience Common is measured differently than its book value, which is the value of Skye that is recorded on the company's balance sheet. Investors also form their own opinion of Skye Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Skye Bioscience's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Skye Bioscience's market value can be influenced by many factors that don't directly affect Skye Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Skye Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Skye Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Skye Bioscience's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.